Since PARP-1 is primarily involved in the DNA repair process, the authors of this study combined EV therapy with cisplatin, which induces DNA damage, and found that decreased expression of PARP-1 enhanced the chemosensitivity of cancer cells to cisplatin, showing synergistic cytotoxicity. Here, PARP1 is linked to cancer.